Introduction
Heterotopic ossification (HO) is a frequent complication after spinal cord injury (SCI) which may represent a significant problem in the rehabilitation process. The incidence of HO varies from 10% to 53% depending on the method of diagnosis.I-3 The patho genesis of HO remains uncertain and the diagnosis is based on radiographic and scintigraphic tests. To date, there is no satisfactory medication for this problem. The recommended prevention of HO with bisphosphonates is not generally accepted, although Stover and coworkers reported a decrease prevalence of HO in patients treated prophylactically with etidronate after SCI. 4,5 These authors also found that patients taking prophylactic etidronate de veloped a significantly smaller amount of HO than the patients taking placebo. 4 Al though there is a well documented benefi cial effect of etidronate on the development of HO, still there are significant differences in the individual responses to medication. The differences in therapeutic response can in part be due to the physicochemical characteristics of the drug. Because of low solubility in water, the reabsorption of bisphosphonates in the intestinal tract fluc tuates from 1% to 10% .6,7 To avoid these variations and to improve bioavailability of etidronate, in this study etidronate was initially administered parenterally and then continued orally with a higher dose8,9 than presently recommended. IO Similar doses of etidronate have been recently introduced in the therapy of hypercalcemia of malig nancy. 11-1 1
Methods

Patients
The patients involved in the study were admitted to the rehabilitation center 2-6 weeks (3.6 ± 1.1 weeks; mean ± SD) after SCI. We studied nonselected patients with HO (two female and 25 male), ranging in age from 16 to 54 (36 ± 6, mean ± SD) years. Quadriplegia was diagnosed in 15 patients (nine complete and six incomplete, Frankel class A) and 12 had paraplegia (11 complete and one incomplete Frankel class B). The diagnosis of HO was based on the presence of clinical symptoms (acute swel ling, reduction of range of motion and increased body temperature), laboratory tests (increased serum alkaline phosphatase and accelerated erythrocyte sedimentation rate), radiographic studies and bone scinti graphy. Three-phase bone scintigram was obtained using technetium 99 m labeled methyl-bisphosphonate. We used scinti graphic criteria for the diagnosis of HO recommended by Freed et al. 1 8 The intra venous therapy was started in patients with the earliest positive findings (phase 1 and 2). Prior to therapy radiographic studies and a venogram were obtained in all patients.
Administration of etidronate
Etidronate disodium (Didronel, Norwich Eaton Pharmaceuticals, Inc, Norwich, NY) was administered in a dose of 300 mg intravenously over a period of 3 hours.
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An infusion was given in the afternoon from 5 pm to 8 pm to avoid interference with the daily rehabilitation program. During intra venous therapy, patients had an indwelling catheter to prevent bladder distension and were encouraged to drink fluid (2-3 I daily). Intravenous etidronate was given for 3 days in 24 patients and 5 days in the remaining three patients. After parenteral therapy, etidronate was administered orally 20 mg/ kg/day for 6 months.9 Radiographic evalu ation was performed every 2 months for the first 6 months and then every 6 months.
Quantitative analysis of soft tissue swelling
For quantitative analysis the circumferences of the thigh and ectopic bone mass were measured. The effect of etidronate on soft tissue swelling was determined by the measurement of thigh circumference 10" above the superior pole of the patella at full knee extension (0°). The measurements were done in bed, in the morning, daily for the first 5 days and then every week. The differences in circumference were expressed in centimeters and used in statistical analy sis.
Quantitative analysis of heterotopic ossification
Quantitative assessment of ectopic bone was determined by planimetry on the radio graphs obtained at least 6 months after intravenous therapy. This part of the study included 24 patients who completed 6 months of therapy. The area of bone mass was measured on anteroposterior view by a compensating polar planimeter 62002 (Keuffeal & Esser, Germany). Two measurements were obtained by two ob servers (FG and KB) and the mean value of the measurements was used for statistical evaluation. The variation between the measurements was less than 1 % . In addition the ectopic mass was determined in a group of 11 SCI patients previously treated with oral etidronate alone. In this grou p , patients were treated initially with 20 mg/kg/day for 2 weeks, followed by 10 mg/kg/day for a period of 6 months. The results in these patients were compared with those obtained in the group treated initially with intra venous therapy and then with 20 mg/kg/ day etidronate for 6 months. Statistical significance between differences was deter mined by the Student's t-test.
Results
Effect on soft tissue swelling
The results of etidronate therapy on soft tissue swelling are summarized in Table I . After intravenous therapy 20 patients showed a prompt reduction of swelling in the period of the first 48 hours (responders), while seven patients showed no changes or had an increase of thigh circumference (nonresponders). The mean reduction of swelling in responders was ( -)3.4 ± 1.4 cm which was significantly lower than the initial measurement (p < 0.01) and also signific antly different than (+ )2.7 ± 1.4 cm in the group of nonresponders (p < 0.001; Table  I ). In the group of nonresponders all seven patients had ipsilateral deep vein thrombo sis in the femoral or iliac vein. In addition to the quantitative changes, in the group of responders there was a considerable qualit ative improvement in the degree of tissue induration, skin temperature and range of motion.
Effect on ectopic ossification Figure 1 shows the subgroups of patients involved in the study. At the entry to the study all 27 patients had clinical and scinti graphic findings of acute HO but only 24
( -)3.4 ± l.4a 0 (2.5-6) (+)2.7 ± 1.4b 7 (0-5) patients completed the 6 months medication protocol. The symptoms of HO developed 28 ± 10 days following SCI; scintigraphic and radiological evaluations were per formed not later than 48 hours after clinical diagnosis. At the time of diagnosis patients had a mean serum alkaline phosphatase concentration of 152 ± 91 units (range 88-322 units/I; normal: 38-126); ESR was elevated in all patients (65 ± 30 mm/h; nor mal < 10 mm/h). In this group, 11 patients also had positive radiographic studies, while 13 patients had no radiographic evidence of HO. In the group of 11 patients, where both scintigraphic and radiographic studies were positive, the area of ectopic bone mass was compared with the area in 12 patients treated only with oral etidronate. orally treated groups. Figure 3 shows the results of 13 patients with a positive bone scan and negative radiographic studies. There were two subgroups. In 10 patients with negative radiographic findings before therapy, eight showed no radiographic evid ence of HO and two had minimal ossifica tion after therapy (Fig 3) . This group of patients were followed for a period of 6-15 months (mean 11.1 months). In the other subgroup (three patients) the medication was interrupted (in two because of surgerv and in one due to noncompliance with or � l medication). These patients developed ectopic ossification in the affected leg after 1-2 months. Figure 3 The mass of HO in SCI patients with out initial radiographic evidence of HO. It is obvious from these data that etidron ate has an inhibitory effect on development of HO. However, there are still a consider able number of patients who fail to respond to therapy. Several studies in animals and humans showed poor intestinal resorption of bisphosphonates.18 It is likely that physicochemical characteristics of the drug may contribute to individual differences in response to therapy. Nakahara et al23 re ported that bioavailability of bisphosphon ates in rats can be increased by parental administration.
I nterru pted therapy
Furthermore, several groups found a dose dependent response in experimentally induced ectopic ossifica tion. 23 . 24 On the basis of these observations we modified the therapeutic protocol and used etidronate initially by intravenous infusion followed by oral administration of 20 mg/ kg/day for 6 months. This oral dose of etidronate was previously suggested by Garland et al. 8 .y The results obtained with such modification of present therapeutic regimen are encouraging. The patients treated early with etidronate, in whom the diagnosis was made by bone scan, showed no evidence of HO in 80% and minimal ossification in 20%. The stage of HO development at which patients start therapy seems related to therapeutic response. In the early stages of HO formation, the mineralization of tissue osteoid is probably inhibited by the iv loading doses of etidron ate and can be maintained in the unmineral ized form with prolonged oral therapy. The effect of therapy at the late stage of HO formation is limited and anatomical changes becomes irreversible. In the later stages, osteoid will undergo mineralization showing radiographic signs of ectopic ossification. Although the number of our patients and time interval of follow up do not permit definitive conclusions, the results show greater therapeutic improvement than pre viously reported.4,5 Using higher doses of etidronate, two important aspects require discussion; the incidence of side effects and the occurrence of HO after withdrawal of etidronate. Nakahara et al23 suggested that the effect of bisphosphonates in animals is transient, because the withdrawal of the drug would cause an immediate appearance of HO. To evaluate this phenomenon further we plan to follow our patients for a longer period (2-3 years) to obtain informa tion on the long term effect of high dose of etidronate. Concerning adverse reactions, serious side effects of bisphosphonate therapy are fractures or renal complications while less significant, though more frequent, are gastrointestinal symptoms. In some of our patients there was no evidence of fractures during the period of 3 years. There are no data available on the incidence of bone fractures in SCI patients treated with bisphosphonates. In Paget's disease, John son et al25 and Khari and Johnson6 were not able to find an increased incidence of fracture rate with doses of etidronate of 20 mg/kg/day even after therapy longer than 6 months. The experiments in animals con firm these clinical observations, that only three-to five-fold higher doses per body weight were associated with bone frac tures.24 It seems that the fractures are more common in elderly subjects, and that younger patients better tolerate higher eti dronate doses. 26 Gastrointestinal symptoms Paraplegia 31 (1993) [660] [661] [662] [663] [664] [665] [666] (nausea and abdominal discomfort) were present in the majority of our patients but these symptoms did not require the discon tinuation of therapy. Renal tests showed no abnormalities after intravenous administra tion of etidronate; it is likely that serious complications occur only in patients with preexisting kidney disease.
Although in this study we planned to focus primarily on the effect on ectopic ossification we found a significant effect of etidronate on soft tissue swelling. A reduc tion of edema and inflammatory reaction was found in all patients in the first 48 hours of intravenous therapy. This effect of eti dronate has not been reported in SCI patients, but similar findings have been seen in patients with Paget's disease2627 and in animals with experimental arthritis.28,29 The mechanism of drug action on the inflam matory process is unknown; recent data suggest that bisphosphonates may have an effect on cell-mediated immune12 and non immune responses.30, 31 We can speculate that some cytokines locally released by inflammatory cells may play a role in the development of hyperemia and exudation. Swiss authors32 reported, using angiography and tissue histology, that prominent vaso dilation and tissue edema are present in an early stage of HO. Our data support these observations and the previous findings re ported in patients with Paget's disease26,27 indicating that local humoral factors, re sponsible for tissue inflammation, will promptly respond to intravenous etidron ate.
Conclusion
Our data indicate that in SCI patients with HO:
1 Intravenous etidronate in doses of 300 mg/day, significantly reduces soft tissue swelling associated with HO within the first 48 hours. 2 A therapeutic protocol using initially intravenous etidronate and then oral dose of 20 mg/kg/day for 6 months had an inhibitory effect on the development of heterotopic bone formation. These pre-liminary results on HO require further investigation III a placebo controlled
